ASX:BNOBionomics Stock Price, Forecast & News

A$0.04

0.00 (0.00 %)

(As of 05/13/2020)

Add

Compare

Today's Range

A$0.04

Now: A$0.04▼

A$0.05

50-Day Range

A$0.04

MA: A$0.05▼

A$0.06

52-Week Range

A$0.03

Now: A$0.04▼

A$0.15

Volume386,458 shs

Average Volume795,392 shs

Market Capitalization$23.42 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancer in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments. The company's product pipeline includes BNC210, a negative allosteric modulator, which is in Phase II clinical trial for the treatment of generalized anxiety disorder, as well as is in Phase II clinical trial in patients with post-traumatic stress disorder; BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that targets cancer stem cells; and BNC105, a vascular disrupting agent for the treatment of cancer, as well as disrupts the blood vessels that nourish tumors in cancer treatment. It also offers Multicore, a suite of integrated synthetic methods that gives access to complex drug-like molecules; and ionX, an integrated platform of genomics discoveries and technologies that serves as the foundation for Bionomics' CNS drug discovery and development, as well as contract research services. The company has a collaborative partnership with Merck & Co., Inc. Bionomics Limited was founded in 1998 and is based in Thebarton, Australia.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Bionomics.

2.5 Community Rank

Outperform Votes
Bionomics has received 54 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Bionomics has received 52 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Bionomics has received 50.94% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Bionomics and other stocks. Vote “Outperform” if you believe BNO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BNO will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Bionomics does not currently pay a dividend.
Dividend Growth
Bionomics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bionomics insiders have not sold or bought any company stock.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Bionomics are expected to grow in the coming year, from A($0.02) to A$0.00 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bionomics is -4.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bionomics is -4.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Bionomics has a P/B Ratio of 2.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

0.63 out of 5 stars

Industry, Sector and Symbol

Stock Exchange ASX

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolASX:BNO

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.bionomics.com.au

Phone+61-8-83546100

Debt

Debt-to-Equity Ratio121.91

Current Ratio1.11

Quick Ratio0.66

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$10.15 million

Price / Sales2.31

Cash FlowA$0.02 per share

Price / Cash Flow2.69

Book ValueA$0.02 per share

Price / Book2.05

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

EmployeesN/A

Outstanding Shares544,686,016

Market Cap$23.42 million

Next Earnings DateN/A

OptionableOptionable

Receive BNO News and Ratings via Email

Sign-up to receive the latest news and ratings for BNO and its competitors with MarketBeat's FREE daily newsletter.

Bionomics (ASX:BNO) Frequently Asked Questions

How has Bionomics' stock been impacted by COVID-19 (Coronavirus)?

Bionomics' stock was trading at A$0.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BNO shares have decreased by 8.5% and is now trading at A$0.04. View which stocks have been most impacted by Coronavirus.

How were Bionomics' earnings last quarter?

Bionomics Ltd (ASX:BNO) posted its quarterly earnings results on Friday, February, 15th. The company reported ($0.02) earnings per share (EPS) for the quarter. View Bionomics' earnings history.

Has Bionomics been receiving favorable news coverage?

News stories about BNO stock have trended somewhat negative on Thursday, according to InfoTrie. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Bionomics earned a daily sentiment score of -1.7 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutBionomics.

Who are some of Bionomics' key competitors?

Some companies that are related to Bionomics include Circassia Pharmaceuticals (CIR), Orgenesis (ORGS), Omega Diagnostics Group (ORPH), Novoheart (NVH), Immunoprecise Antibodies (IPA), Ampio Pharmaceuticals (AMPE), Acasti Pharma (ACST), Biopharmx (BPMX), AquaBounty Technologies (AQB), Orthocell (OCC), Synairgen (SNG), Cynata Therapeutics (CYP), Oxford Biodynamics (OBD), Pediapharm (PDP) and 4d Pharma (DDDD). View all competitors.

What other stocks do shareholders of Bionomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bionomics investors own include McDermott International (MDR), Adamas Pharmaceuticals (ADMS), ADMA Biologics (ADMA), AcelRx Pharmaceuticals (ACRX), Aclaris Therapeutics (ACRS), AC Immune (ACIU), Acer Therapeutics (ACER), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS) and ABIOMED (ABMD).

Who are Bionomics' key executives?

Bionomics' management team includes the following people:

Dr. Errol B. De Souza, Exec. Chairman (Age 66)
Mr. Jack Moschakis BEc, DipLaw(BAB), GDipBA, FCIS, Legal Counsel & Company Sec.
Prof. Paul Rolan, Consultant Medical Officer of Clinical Neuroscience

What is Bionomics' stock symbol?

Bionomics trades on the ASX under the ticker symbol "BNO."

What is Bionomics' stock price today?

One share of BNO stock can currently be purchased for approximately A$0.04.

How big of a company is Bionomics?

Bionomics has a market capitalization of $23.42 million and generates $10.15 million in revenue each year.

What is Bionomics' official website?

The official website for Bionomics is www.bionomics.com.au.

How can I contact Bionomics?

Bionomics' mailing address is 31 Dalgleish St, THEBARTON, SA 5031, Australia. The company can be reached via phone at +61-8-83546100.

This page was last updated on 5/28/2020 by MarketBeat.com Staff